Navigation Links
Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
Date:6/25/2010

(this,'o','ExternalLink');" target='_blank' href="http://www.Vpriv.com">http://www.Vpriv.com.

Important Safety Information

The most serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.

Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia. Generally the infusion-related reactions were mild and, in treatment-naive patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. Other commonly observed adverse reactions in [greater than or equal to]10% of patients were: abdominal pain, back pain, joint pain, upper respiratory tract infection, and activated partial thromboplastin time prolonged. Adverse reactions more commonly seen in pediatric patients (>10% difference) included upper respiratory tract infection, rash, activated partial thromboplastin time prolonged, and pyrexia.

In clinical trials one patient developed neutralizing antibodies.

About Gaucher Disease

Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. This enzymatic deficiency causes an accumulation of glucocerebroside, primarily in macrophages. In this lysosomal storage disorder, clinical features are reflective of the distribution of Gaucher cells in the liver, spleen, bone marrow, and other organs. The accumulation of glucocerebroside in the liver and spleen leads to organomegaly. Presence of Gaucher cells in the bone marrow and spleen lead to cl
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire plc Appoints Two New Board Directors
2. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
3. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
4. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
5. Shires Replenished Portfolio Drives Excellent Quarterly Performance
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Shire Supports Rare Disease Day 2010
8. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
9. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
10. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
11. New Shire Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/27/2014)... Varian Medical Systems today broke ground ... Lake City manufacturing facility and allow for the consolidation ... create 1,000 new full time jobs in the state ... home to hardworking people with immense engineering and technical ... success in the manufacturing of our state-of-the-art X-ray technology,” ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 /PRNewswire/ ... research report is available in its catalogue: ... 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials are materials that are readily decomposed ... differs from conventional non-degradable packaging in terms ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... p.m. EDT -, VALENCIA, Calif., Aug. 11 ... for the second,quarter ended June 30, 2008., For ... $80.9,million, compared to $75.4 million for the second quarter ... and development,(R&D) expenses which totaled $67.6 million for this ...
... Aug. 11 Immtech Pharmaceuticals,Inc. (Amex: IMM ) ... 2008., For the three months ended June 30, ... three months ended June 30, 2007. The increase,was primarily ... from operations for the three months ended June 30, ...
... Informed Medical Communications,(IMC), a leading provider of ... position today on recent revisions,to the PhRMA Code. ... Code," noted Dr. Jaime Nguyen, Medical Director/Compliance Officer,for ... continually monitored,the compliance trends so that our services ...
Cached Biology Technology:MannKind Corporation Reports Second Quarter Financial Results 2MannKind Corporation Reports Second Quarter Financial Results 3MannKind Corporation Reports Second Quarter Financial Results 4MannKind Corporation Reports Second Quarter Financial Results 5MannKind Corporation Reports Second Quarter Financial Results 6Immtech Reports Fiscal First Quarter 2009 Results 2Immtech Reports Fiscal First Quarter 2009 Results 3Informed Medical Communications Highlights Opportunity in Revised PhRMA Code 2
(Date:8/28/2014)... Researchers at the University of Minnesota have developed an ... be used for muscle regeneration research as well as ... , The research is published in the current edition ... is no treatment for FSHD, which is thought by ... dystrophy. FSHD is an unusual genetic disorder because, unlike ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
(Date:8/28/2014)... More than 25 million kilometres of new roads will ... will slice into Earth,s last wildernesses, where they bring ... , Now, an ambitious study has created a ... to try to balance the competing demands of development ... an ,environmental-values, layer that estimates that natural importance of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... This press release is available in Spanish ... losses to the atmosphere through volatilization also rise. ... (USDA) scientists found that herbicide volatilization consistently resulted in ... Agricultural Research Service (ARS) soil scientist Timothy ...
... it has not stopped her from working. Thanks in part ... her 13th year as an account executive for a firm ... are not as fortunate. In the United States, the ... as systemic sclerosis, is two to three times that of ...
... of scientists has produced a new map of the ... an ultra-nutritious potato that could help feed the world,s ... genome of the potato, the consortium has, for the ... Resulting insights into the growth and development of potatoes ...
Cached Biology News:Researchers study pesticide pathways into the atmosphere 2Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
Request Info...
... Nebulizers are available in two product models - ... two models is that the 6000AT+ includes a ... drier aerosol for improved detection limits and reduced ... a range of elements by 10-40 times. Note ...
Biology Products: